よむ、つかう、まなぶ。
04 参考資料１－１23価肺炎球菌莢膜ポリサッカライドワクチン（肺炎球菌ワクチン）ファクトシート (32 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_36630.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第22回 12／1）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
who receive seasonal influenza vaccine in Japan. Vaccine. 28:7063-9,2010.
57．Maruyama T, Taguchi O, Niederman MS, Moser J, Kobayashi H, Kobayashi T, et al. Efficacy
of 23-valet pneumococcal vaccine in preventing pneumonia and improving survival in nursing
home residents: double blind, randomized and placebo controlled trial. BMJ. 340: c1004,
2010,
58．Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al.
Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against
pneumococcal pneumonia in adults aged 65 years or older: a multicenter, prospective,
test-negative design study. Lancet Infect Dis. 17:313-21,2017.
59．Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C.
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against
pneumococcal disease in the elderly: systemic review and meta-analysis. PLoS One.
6;12(1):e0169368. Doi:10.1371/journal.pone.
60．Kraicer-Melamed H, O’Donnell S, Quach C. The effectiveness pf pneumococcal polysaccharide
vaccine 23 (PPV23) in the general population of 50 years of age and older: a systemic review
and meta-analysis. Vaccine 34: 1540-50, 2016
61．大石和徳、大島信治、川上和義、川上健司、永井英明、渡辺 彰.肺炎球菌ワクチン再接種のガ
イダンス.感染症学雑誌.91:543-52,2017
62．Musher DM, Manoff SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, et al. Safety and
antibody response, including antibody persistence for 5 years, after primary vaccination
or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
J Infect Dis. 201:516-24, 2010.
63．Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, et al. Safety of
revaccination with pneumococcal polysaccharide vaccine. JAMA. 281:243-8, 1999.
64．Remschmidt C, Harder T, Wichmann O, Bogdan C, Falkenhorst G. Effectiveness, immunogenicity
and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly:
a systematic review. BMC Infect Dis. 25:16(1):711, 2016.
65．第 34 回厚生科学審議会予防接種・ワクチン分科会副反応検討部会、平成 29 年度第 13 回薬事・
食品衛生審議会医薬品等安全対策部会安全対策調査会(合同開催) 会議資料 7. 23 価肺炎球菌ワ
クチンの副反応疑い報告状況について. 1-32, 2017.
31
57．Maruyama T, Taguchi O, Niederman MS, Moser J, Kobayashi H, Kobayashi T, et al. Efficacy
of 23-valet pneumococcal vaccine in preventing pneumonia and improving survival in nursing
home residents: double blind, randomized and placebo controlled trial. BMJ. 340: c1004,
2010,
58．Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al.
Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against
pneumococcal pneumonia in adults aged 65 years or older: a multicenter, prospective,
test-negative design study. Lancet Infect Dis. 17:313-21,2017.
59．Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C.
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against
pneumococcal disease in the elderly: systemic review and meta-analysis. PLoS One.
6;12(1):e0169368. Doi:10.1371/journal.pone.
60．Kraicer-Melamed H, O’Donnell S, Quach C. The effectiveness pf pneumococcal polysaccharide
vaccine 23 (PPV23) in the general population of 50 years of age and older: a systemic review
and meta-analysis. Vaccine 34: 1540-50, 2016
61．大石和徳、大島信治、川上和義、川上健司、永井英明、渡辺 彰.肺炎球菌ワクチン再接種のガ
イダンス.感染症学雑誌.91:543-52,2017
62．Musher DM, Manoff SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, et al. Safety and
antibody response, including antibody persistence for 5 years, after primary vaccination
or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
J Infect Dis. 201:516-24, 2010.
63．Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, et al. Safety of
revaccination with pneumococcal polysaccharide vaccine. JAMA. 281:243-8, 1999.
64．Remschmidt C, Harder T, Wichmann O, Bogdan C, Falkenhorst G. Effectiveness, immunogenicity
and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly:
a systematic review. BMC Infect Dis. 25:16(1):711, 2016.
65．第 34 回厚生科学審議会予防接種・ワクチン分科会副反応検討部会、平成 29 年度第 13 回薬事・
食品衛生審議会医薬品等安全対策部会安全対策調査会(合同開催) 会議資料 7. 23 価肺炎球菌ワ
クチンの副反応疑い報告状況について. 1-32, 2017.
31